From the NIHR website:
https://fundingawards.nihr.ac.uk/award/NIHR174857
Research Award
Active Award
Award ID: NIHR174857
Shortlist:
Health Effects fRom Infection sequelae: Tailoring services and Advancing GuidancE (HERITAGE) in Long Covid and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Plain English Summary:
BACKGROUND:
Persistent Long covid (LC) or post-COVID syndrome, defined as LC present for > 2 years and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are long-term conditions that together affect > 1.5 million people in the UK alone and > 60 million worldwide. Both conditions have significant overlapping symptoms, are linked to infections, and have some common underlying pathophysiology.
The burden to the UK economy per year is estimated to be £8.1 billion for LC and £3.3 billion for ME/CFS. These two conditions are nevertheless not adequately prioritised by National Health Service (NHS) services (many LC clinics are closing, and many UK areas lack ME/CFS clinics) and lack research funding. There is an urgent need for health services research and developing a National Service Framework that will improve care in existing services and effectively reduce the overall costs to the NHS and the UK economy.
In the NIHR-funded health services LOCOMOTION study (2021-2024), we acquired expertise, skills and databases in LC that will help deliver HERITAGE at a lower cost to funder and maximise the opportunity to develop a National Service Framework for ME/CFS and LC.
AIMS AND OBJECTIVES: The study in ME/CFS and LC aims to: 1) explore the overlap, long-term trajectory of symptoms, and clinical outcomes; 2) assess the healthcare utilisation and cost-effectiveness of different service models (including analysing costs and outcomes in a national cohort with no access to clinics); 3) develop a national service framework to improve quality of care in both conditions
METHODS:
WP1: Map the clinical course and health costs over 12 months in persistent LC (1250 patients complete datasets) and ME/CFS (250 patients) via our validated DPROM platform from three established sites (with different integration models) and a non-clinic national cohort (who have either no access to specialist clinic or no clinics in their area);
WP2: estimate the cost-effectiveness of three service models and also compare to UK-wide non-clinic cohort using validated PROMs for LC and ME/CFS, EQ5D-5L, healthcare utilisation, vocational productivity loss, carer burden and Quality Adjusted Life Year (QALY) estimates; and
WP3: exploring quality of care using qualitative interviews and set up a Quality Improvement Collaborative (QIC) to improve care in both conditions informed by the principles of action research and generate training resources and transferable lessons for a National Service Framework for ME/CFS and LC.
PPI: The HERITAGE bid was co-developed with a diverse group of UK-wide lived-experience patients from both conditions, charities, and policymakers. The PPI team will be equal partners in research, co-produce research outputs, and help engage stakeholders.
IMPACT AND DISSEMINATION:
HERITAGE will inform the development of evidence-based, cost-effective NHS service models for LC and ME/CFS. The national service framework will improve quality of life, reduce vocational disability, reduce economic burden, and potentially be applicable to other post-infection syndromes and strengthen our pandemic preparedness. Dissemination will be via our already established channels with all UK LC and ME/CFS clinics, the National Post-Covid Society (CPCS), World Health Organisation, All Party Parliamentary Groups (APPG), NHS Integrated Care Boards (ICBs), patient charities, and research funders.
Abstract:
One million individuals in the UK have the long-term condition of Long COVID (symptoms for more than 2 years). Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) is estimated to affect half a million UK people. These two conditions are related to infections, have overlapping symptoms that include severe fatigue, post-exertional malaise, cognitive problems, unrefreshing sleep, chronic pain, problems in daily activities and work.
The total health and social care costs, including lost productivity, caregiver costs, and value of lost health, are estimated to be £8.1 billion/ year for Long COVID and £3.3 billion/year for ME/CFS.
Both conditions are not prioritised by clinicians and researchers, are currently treated in disjointed services, and many individuals have no access to specialist clinics.
There's a need for research to improve the quality of existing specialist services, introduce new services, and enable better care for all individuals affected by these common long-term conditions.
Our previous study LOCOMOTION (2021-2024) funded by the NIHR for Long COVID enabled us to develop skills in standardising and improving quality of care, test a digital platform for collecting outcomes and analyse healthcare costs; these skills and resources can now be applied in this proposal (HERITAGE) to enable best value for money for the funder.
Aims of the HERITAGE study
1. To understand how the symptoms of Long COVID and ME/CFS overlap, and progress over time
2. To capture healthcare costs and carer burden and discover which of the current healthcare models (No specialist care or LC/ ME/CFS specialist care) are the best value for money
3. To improve the quality of Long COVID and ME/CFS healthcare and ensure the best standard of care is available to all nationally
How the study will be done
Work Package 1 (WP1): Use our existing digital platform to collect data on how ME/CFS and Long COVID are diagnosed by healthcare professionals, their symptoms and how much the two conditions overlap and affect people over time.
WP2: Compare the costs and effectiveness of the different existing service models in terms of integration between Long COVID and ME/CFS clinics (including comparing with healthcare, economic and societal costs in a separate UK-wide group having no access to specialist clinics).
WP3: Talk to patients, healthcare workers, and other stakeholders to understand what's working well and what needs to change, and how to address systemic barriers of stigma, disbelief, race, culture and social deprivation.
HERITAGE will develop a national system of services and offer training and resources for all specialist services and primary care across the UK.
Patient and Public Involvement (PPI)
The proposal has already involved people with lived experience of Long COVID and ME/CFS from a wide range of backgrounds and UK locations. This group will continue to shape every aspect of the study from start to finish. A dedicated research inclusion group will ensure a range of voices are heard.
Dissemination and Stakeholder Engagement
The study findings will be shared with healthcare organisations, including the Department of Health, national clinical and research networks, NHS services, Integrated Care Boards, and relevant All-Party Parliamentary Groups. Impact This research will improve healthcare for an estimated 1.5 million people in the UK, and determine high-quality, cost-effective service provision for Long COVID and ME/CFS
Chief Investigator(s):
Professor Manoj Sivan
Co-investigators:
Dr Darren Greenwood,
Dr Gemma Hughes,
Dr Harsha Master,
Dr Joseph Kwon,
Dr Stephen Halpin,
Dr Vikki McKeever,
Professor Rachael Evans Professor Stavros Petrou
Award:
£1,389,206.23
Programme:
Health and Social Care Delivery Research
Health Category(s):
Infection,
Other
Research Activity(s):
8.1 Organisation and delivery of services
Start Date:
January 2026
End Date:
June 2028
Contracting Organisation:
University of Leeds
Research Call:
HSDR Researcher-led call (November 24 - March 25)
Programme Stream:
Researcher Led
Funding Stream:
HSDR Researcher